These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

89 related articles for article (PubMed ID: 6879539)

  • 21. Influence of calcium channel blocker drugs in neuromuscular transmission.
    Ozkul Y
    Clin Neurophysiol; 2007 Sep; 118(9):2005-8. PubMed ID: 17644037
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Isoptin in the prevention of post-resuscitation damage of the heart].
    Dolgikh VT
    Patol Fiziol Eksp Ter; 1986; (6):21-5. PubMed ID: 3822530
    [No Abstract]   [Full Text] [Related]  

  • 23. Use of calcium channel blockers in hypertension.
    Conlin PR; Williams GH
    Adv Intern Med; 1998; 43():533-62. PubMed ID: 9506192
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Obesity in the service of Justice. New drug-combination leads to protection of the kidney].
    Streier K
    Fortschr Med; 1997 Nov; 115(32):54-5. PubMed ID: 9480271
    [No Abstract]   [Full Text] [Related]  

  • 25. [Evaluation of the antihypertensive efficacy and safety of using sustained release verapamil in elderly subjects using ambulatory blood pressure monitoring].
    Jasiński T; Janicki K; Klima M; Pieniazek W; Bednarz S
    Przegl Lek; 1996; 53(2):73-7. PubMed ID: 8754325
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Evaluation of hypotensive and antiischemic effects of a combination of dihydropyridine and non-dihydropyridine calcium antagonists in patients suffering from coronary artery disease with arterial hypertension].
    Iskendeerov BG; Burmistrova LF; Berenshteĭn NV; Abramova GN; Lokhina TV; Shibaeva TM
    Klin Med (Mosk); 2006; 84(11):52-6. PubMed ID: 17243612
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Verapamil-sustained release-based treatment strategy is equivalent to atenolol-based treatment strategy at reducing cardiovascular events in patients with prior myocardial infarction: an INternational VErapamil SR-Trandolapril (INVEST) substudy.
    Bangalore S; Messerli FH; Cohen JD; Bacher PH; Sleight P; Mancia G; Kowey P; Zhou Q; Champion A; Pepine CJ;
    Am Heart J; 2008 Aug; 156(2):241-7. PubMed ID: 18657652
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Calcium-channel antagonists in cardiovascular disease.
    Holdright DR
    Br J Hosp Med; 1997 Jun 4-17; 57(11):552-6. PubMed ID: 9307671
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparison of bisoprolol and verapamil in hypertension: influence on left ventricular mass and function--a pilot study.
    Gosse P; Gressin V; Clerson P; Lemetayer P; Clémenty J
    Therapie; 1999; 54(2):217-22. PubMed ID: 10394257
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Verapamil retard as a medication for the prevention of affective and schizoaffective psychosis relapses].
    Raiushkin VA
    Zh Nevrol Psikhiatr Im S S Korsakova; 2002; 102(10):52-7. PubMed ID: 12449566
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prevention of microalbuminuria in type 2 diabetes: millimeters or milligrams?
    Glassock RJ
    J Am Soc Nephrol; 2006 Dec; 17(12):3276-8. PubMed ID: 17108313
    [No Abstract]   [Full Text] [Related]  

  • 32. Calcium channel blockers: an evidence-based review.
    Waters D
    Can J Cardiol; 1997 Aug; 13(8):757-66. PubMed ID: 9284842
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Calcium channel blockers in cirrhotic patients with portal hypertension.
    Li D; Lu H; Li X; Quan Q; Li X; Lu W
    Chin Med J (Engl); 1995 Nov; 108(11):803-8. PubMed ID: 8585970
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Current status of safety and efficacy of calcium channel blockers in cardiovascular diseases: a critical analysis based on 100 studies.
    Opie LH; Yusuf S; Kübler W
    Prog Cardiovasc Dis; 2000; 43(2):171-96. PubMed ID: 11014332
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Long-term treatment with calcium antagonists: advantageous effects and risks].
    van Zwieten PA; Tijssen JG; Lie KI; de Leeuw PW
    Ned Tijdschr Geneeskd; 1995 Dec; 139(52):2715-21. PubMed ID: 8569884
    [No Abstract]   [Full Text] [Related]  

  • 36. The use of calcium channel blockers in general practice.
    Tonkin A; Frewin D
    Aust Fam Physician; 1993 Mar; 22(3):389-95. PubMed ID: 8466450
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Use of isoptin SR-240 in treatment of hypertension].
    Knypl K; Brym E; Wacławek-Maczkowska J
    Wiad Lek; 1993 Dec; 46(23-24):898-901. PubMed ID: 7900385
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comment to: addition of verapamil in the treatment of severe myoclonic epilepsy in infancy (Iannetti et al.).
    Striano P
    Epilepsy Res; 2009 Sep; 86(1):97-8. PubMed ID: 19481907
    [No Abstract]   [Full Text] [Related]  

  • 39. [Views on the use of calcium channel blockers in the treatment of heart ischemia and hypertension].
    Halawa B
    Pol Merkur Lekarski; 1998 Sep; 5(27):107-10. PubMed ID: 10101470
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Sex difference in response of blood pressure to calcium antagonism in the treatment of moderate-to-severe hypertension.
    Loeb ED; Diamond JA; Krakoff LR; Phillips RA
    Blood Press Monit; 1999 Oct; 4(5):209-12. PubMed ID: 10547639
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.